Get Real Stocks

ABVX · Abivax SA

Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology
Country
France

ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.

24h Volume by Exchange

No Data Yet

Issuer
Price
$116.34
24h Volume
-
Depth (±1%)
-